NEUMORA THERAPEUTICS, INC.
NASDAQ: NMRA (Neumora Therapeutics, Inc.)
Last update: 5 hours ago3.02
0.02 (0.67%)
| Previous Close | 3.00 |
| Open | 2.96 |
| Volume | 1,075,887 |
| Avg. Volume (3M) | 1,625,888 |
| Market Cap | 513,214,112 |
| Price / Book | 3.92 |
| 52 Weeks Range | |
| Earnings Date | 9 Mar 2026 |
| Diluted EPS (TTM) | -1.61 |
| Total Debt/Equity (MRQ) | 0.41% |
| Current Ratio (MRQ) | 8.98 |
| Operating Cash Flow (TTM) | -199.43 M |
| Levered Free Cash Flow (TTM) | -108.00 M |
| Return on Assets (TTM) | -48.51% |
| Return on Equity (TTM) | -79.05% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Neumora Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 0.5 |
| Average | -0.63 |
|
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 27.57% |
| % Held by Institutions | 60.62% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Softbank Group Corp. | 31 Dec 2025 | 6,429,720 |
| Mic Capital Management Uk Llp | 31 Dec 2025 | 4,460,700 |
| Point72 Asset Management, L.P. | 31 Dec 2025 | 3,673,839 |
| Wellcome Trust Ltd (The) As Trustee Of The Wellcome Trust | 31 Dec 2025 | 3,309,123 |
| Iconiq Capital, Llc | 31 Dec 2025 | 2,559,090 |
| Lunate Capital Ltd | 31 Dec 2025 | 2,124,143 |
| Johnson & Johnson | 31 Dec 2025 | 1,849,445 |
| Renaissance Technologies Llc | 31 Dec 2025 | 1,445,902 |
| Ikarian Capital, Llc | 31 Dec 2025 | 1,278,408 |
| 52 Weeks Range | ||
| Median | 8.00 (164.90%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Leerink Partners | 12 Jan 2026 | 8.00 (164.90%) | Buy | 2.22 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 04 Feb 2026 | Announcement | Neumora Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026 |
| 05 Jan 2026 | Announcement | Neumora Therapeutics Highlights 2026 Pipeline Strategy and Anticipated Upcoming Milestones |
| 05 Jan 2026 | Announcement | Neumora Therapeutics Announces Positive Results from NMRA-511 Phase 1b Signal-Seeking Study in Alzheimer’s Disease Agitation |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |